• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Copegus, the brand name for the antiviral drug ribavirin, is a nucleoside analogue that has played a pivotal role in the treatment of chronic hepatitis C virus (HCV) infection, particularly when used in combination with interferon-based therapies and, more recently, with direct-acting antivirals (DAAs). Although newer, interferon-free regimens have largely replaced ribavirin in many settings, Copegus remains an important component in certain patient populations and for specific HCV genotypes. This report provides a brief overview of Copegus, including its mechanism of action, clinical indications, administration, side effects, and current role in HCV therapy.

Mechanism of Action
Ribavirin is a synthetic nucleoside analogue of guanosine, which exhibits broad-spectrum antiviral activity against a range of RNA and DNA viruses. Its precise mechanism against HCV is not fully understood, but several actions have been proposed. Ribavirin is thought to inhibit viral RNA-dependent RNA polymerase, interfere with the capping of viral mRNA, and deplete intracellular guanosine triphosphate pools, thereby suppressing viral replication. Additionally, it may promote viral mutagenesis, leading to error catastrophe, and modulate the host immune response by shifting the T-cell balance from Th2 to Th1 phenotype, which enhances clearance of infected cells. In combination with interferon or DAAs, ribavirin appears to reduce relapse rates and improve sustained virologic response (SVR) in certain settings.

Clinical Indications
Copegus was first approved by the U.S. Food and Drug Administration (FDA) in 2003 for use with peginterferon alfa-2a or -2b in the treatment of chronic HCV infection in adults. The combination therapy (peginterferon plus ribavirin) was the standard of care for many years, achieving SVR rates of about 40–80% depending on HCV genotype, viral load, and patient characteristics. However, the advent of DAAs—such as sofosbuvir, ledipasvir, and daclatasvir—has transformed HCV treatment, allowing for all-oral, interferon-free regimens with SVR rates exceeding 95% in most patients. Today, Copegus is used primarily as an add-on to DAA-based therapy in select cases, such as:

• Genotype 3 infection: Ribavirin remains recommended in combination with sofosbuvir plus daclatasvir or sofosbuvir/velpatasvir for patients with compensated cirrhosis, as it reduces the risk of relapse.
  
• Prior treatment failure: For patients with decompensated cirrhosis or who have failed a DAA regimen, ribavirin may be added to improve SVR.
  
• HCV/HIV coinfection: In some guidelines, ribavirin is considered for those with advanced liver disease or unfavorable host factors.
  
• Hepatitis C in kidney or liver transplant recipients: Ribavirin may be used cautiously with DAAs due to interactions and patient tolerance.
  
  

Copegus is not recommended for monotherapy, as it is ineffective alone against HCV.

Administration and Dosage
Copegus is available as oral tablets (200 mg) and capsules. The dosage is weight-based: typically 800–1400 mg daily (divided into two doses) when used with peginterferon. In DAA combinations, the dose is often lower (e.g., 600–1000 mg/day). The duration of therapy varies from 12 to 48 weeks depending on the regimen and patient response. Ribavirin is excreted renally, so dose adjustments are necessary for patients with impaired kidney function; it is contraindicated in those with creatinine clearance below 50 mL/min due to risk of accumulation and severe hemolytic anemia.

Side Effects and Safety
The most common and clinically significant adverse effect of Copegus is hemolytic anemia, which can lead to significant decreases in hemoglobin levels within the first 1–2 weeks of therapy. This anemia is dose-dependent and often requires dose reduction or discontinuation. Patients with pre-existing cardiac disease or anemia are at higher risk for serious cardiovascular events. Other side effects include fatigue, headache, insomnia, nausea, and rash. Ribavirin is also teratogenic, with both male and female patients (and their partners) required to use effective contraception during treatment and for six months after completion. Monitoring of hemoglobin, bilirubin, and reticulocyte counts is essential during therapy.

Drug Interactions
Ribavirin may interact with didanosine (increased toxicity) and azathioprine (risk of severe pancytopenia). It also reduces the effect of warfarin. With DAA medications, interactions are generally not significant, but caution is needed when used with drugs that affect renal function.

Current Status and Future Directions
In the current DAA era, Copegus is no longer a first-line agent for 5mg €0.86 — Tadalafil - http://farmacianovapatraix.es/, most HCV patients. However, it retains a niche role for difficult-to-treat populations, especially in resource-limited settings where DAA access may be restricted. Ongoing research is exploring ribavirin's potential in combination with new antivirals for other viruses, such as SARS-CoV-2, though results have been variable. The World Health Organization (WHO) still lists ribavirin as an essential medicine for hepatitis C in specific contexts.

Conclusion
Copegus (ribavirin) has been a cornerstone in HCV therapy for over two decades. While its use has diminished with the arrival of highly effective DAAs, it remains a valuable tool in selected patients with advanced disease, previous treatment failure, or genotype 3 infection. Understanding its mechanism, side effects, and appropriate indications is crucial for clinicians managing hepatitis C. As therapy evolves further, ribavirin’s role may continue to shrink, but for now, it persists as a key component in the armamentarium against HCV.